{"id":784273,"date":"2023-09-15T07:27:13","date_gmt":"2023-09-15T11:27:13","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-announces-first-patients-with-small-cell-lung-cancer-dosed-in-hpn328-combination-cohort\/"},"modified":"2023-09-15T07:27:13","modified_gmt":"2023-09-15T11:27:13","slug":"harpoon-therapeutics-announces-first-patients-with-small-cell-lung-cancer-dosed-in-hpn328-combination-cohort","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-announces-first-patients-with-small-cell-lung-cancer-dosed-in-hpn328-combination-cohort\/","title":{"rendered":"Harpoon Therapeutics Announces First Patients with Small Cell Lung Cancer Dosed in HPN328 Combination Cohort"},"content":{"rendered":"
\n

SOUTH SAN FRANCISCO, Calif., Sept. 15, 2023 (GLOBE NEWSWIRE) — Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced dosing of the first patients with small cell lung cancer (SCLC) in an ongoing Phase 1\/2 trial of HPN328, a DLL3 targeting TriTAC\u00ae<\/sup>, in combination with atezolizumab (Tecentriq\u00ae<\/sup>). Harpoon previously entered a Master Clinical Supply Agreement with F. Hoffmann-La Roche for the supply of atezolizumab. Under this agreement, Harpoon is the sponsor of the trial and Roche will supply atezolizumab. This announcement is being made in conjunction with Harpoon\u2019s investor event, \u201cDLL3 Market Opportunity and KOL Discussion of HPN328,\u201d held virtually and in person today in New York beginning at 8 a.m. ET.<\/p>\n

\u201cDosing the first patients in these combination cohorts for HPN328 with atezolizumab in patients with SCLC marks a significant milestone for this clinical program,\u201d said Luke Walker, M.D., Chief Medical Officer for Harpoon Therapeutics. \u201cBuilding on the strength of our Phase 1 data, we remain committed to realizing the full potential of HPN328 as an important treatment option for patients with SCLC and other neuroendocrine tumors across early and late lines of therapy.\u201d<\/p>\n

\n About the HPN328 + Atezolizumab Combination Cohort <\/strong>
\n
Previously treated extensive stage SCLC patients enrolled in these combination cohorts will be dosed with HPN328 administered once every 2 weeks (Q2W) by IV infusion during each 28-day cycle. Atezolizumab will be administered once every 4 weeks (Q4W) by IV infusion on day 1 of each 28-day cycle. Primary outcome measures will include frequency and severity of treatment emergent adverse events (TEAEs), number and severity of dose limiting toxicities (DLTs), and pharmacokinetic parameters. Secondary outcome measures will include objective response rate (ORR), progression-free survival (PFS), overall survival (OS), duration of response (DOR), and anti-drug antibody (ADA) formation. Enrollment in the combination cohorts has been initiated at the 12 mg Q2W HPN328 dose level, and escalation is planned per protocol dependent on data, with initial results from these combination cohorts expected in 2024. Separately, HPN328 interim Phase 1 monotherapy data will be presented at the European Society for Medical Oncology (ESMO)\u00a0held\u00a0on October 20-24, 2023.<\/p>\n

\n Webcast Information for \u201cDLL3 Market Opportunity and KOL Discussion of HPN328\u201d<\/strong>\n <\/p>\n